Opioid Induced Constipation Drug Market Overview
As per MRFR analysis, the Opioid Induced Constipation Drug Market Size was estimated at 1.63 (USD Billion) in 2022.
The Opioid Induced Constipation Drug Industry is expected to grow from 1.71(USD Billion) in 2023 to 2.7 (USD Billion) by 2032. The Opioid Induced Constipation Drug Market CAGR (growth rate) is expected to be around 5.18% during the forecast period (2024 - 2032).
Key Opioid Induced Constipation Drug Market Trends Highlighted
The Opioid Induced Constipation Drug market exhibits promising growth prospects, driven by several key factors. The increasing prevalence of opioid-induced constipation, coupled with the growing awareness of its debilitating effects, is a major driver. Additionally, the introduction of novel drug formulations and the expansion of patient access to these therapies are fueling market growth.
A competitive environment with established players and emerging companies characterizes the market landscape. Key market drivers include the rise in opioid use, technological advancements, and the expansion of healthcare infrastructure in emerging markets. Opportunities for growth are present in the development and commercialization of new drug formulations, personalized treatment approaches, and the integration of digital health technologies.
Recent trends in the Opioid Induced Constipation Drug market include the growing adoption of non-opioid therapies, such as laxatives and enemas. The shift towards patient-centric care and the integration of telemedicine services are also shaping market dynamics. Furthermore, the increasing focus on reducing opioid misuse and addiction is likely to drive the development of safer and more effective constipation management strategies.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Opioid Induced Constipation Drug Market Drivers
Rising Prevalence of Opioid-Induced Constipation (OIC)
Opioid-induced constipation (OIC) is a common and debilitating side effect of opioid use, affecting up to 90% of patients. The increasing prevalence of opioid use, particularly for chronic pain management, is driving the demand for effective OIC treatments. The Opioid Induced Constipation Drug Market Industry is expected to witness significant growth as a result of this growing patient population.
Increasing Awareness and Recognition of OIC
Historically, OIC has been under-recognized and undertreated. However, growing awareness among healthcare professionals and patients about the impact of OIC on quality of life is leading to increased diagnosis and treatment. This increased recognition is contributing to the growth of the Opioid Induced Constipation Drug Market Industry.
Development of Novel and More Effective Therapies
Ongoing research and development efforts are resulting in the introduction of novel and more effective OIC treatments. These new therapies offer improved efficacy, reduced side effects, and more convenient administration, making them more appealing to patients and healthcare providers. The availability of these innovative treatments is expected to drive further the growth of the Opioid Induced Constipation Drug Market Industry.
Opioid Induced Constipation Drug Market Segment Insights:
Opioid Induced Constipation Drug Market Opioid Type Insights
The Opioid Induced Constipation Drug Market is segmented by Opioid Type into Agonists, Partial Agonists, Mixed Agonists/Antagonists, and Antagonists. Among these, Agonists held the largest market share in 2023, accounting for over 45% of the global revenue. This dominance is attributed to the widespread use of opioids, such as morphine and oxycodone, in pain management, which often leads to constipation as a side effect. Agonists work by binding to opioid receptors in the gut, reducing the propulsive movements of the intestines and causing constipation.
The market for Agonists is expected to continue growing steadily in the coming years, driven by the rising prevalence of chronic pain conditions and the increasing use of opioids for pain relief. Partial Agonists, which have both agonist and antagonist properties, accounted for a significant share of the market in 2023 and are projected to maintain a steady growth rate in the coming years. Partial Agonists are often used to manage pain while minimizing the constipating side effects associated with full agonists. Mixed Agonists/Antagonists, which have both agonist and antagonist effects at different opioid receptors, have a smaller market share compared to Agonists and Partial Agonists.
However, their unique mechanism of action, which allows for pain relief with reduced constipation, is expected to drive their market growth in the coming years. Antagonists, which block the effects of opioids at opioid receptors, accounted for the smallest market share in 2023. Antagonists are primarily used to reverse the effects of opioid overdose and are not typically prescribed for the treatment of opioid-induced constipation. The market for Antagonists is expected to remain relatively small in the coming years, with limited growth potential.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Opioid Induced Constipation Drug Market Drug Class Insights
The Opioid Induced Constipation Drug Market segmentation by Drug Class, such as Peripherally Acting Opioid Receptor Antagonists, Peripherally Acting Non-Opioid Receptor Agonists, Centrally Acting Laxatives, and Osmotic Laxatives, allows for a comprehensive analysis of the market landscape. Among these segments, Peripherally Acting Opioid Receptor Antagonists emerged as the dominant category, capturing approximately 60% of the Opioid Induced Constipation Drug Market revenue in 2023. The widespread adoption of drugs like naloxegol and methylnaltrexone, which effectively counteract opioid-induced constipation without affecting analgesia, has contributed to this segment's growth.
The remaining market share is divided among Peripherally Acting Non-Opioid Receptor Agonists (25%), Centrally Acting Laxatives (10%), and Osmotic Laxatives (5%). These segments offer alternative treatment options for patients experiencing constipation due to opioid use. As the prevalence of opioid-induced constipation continues to rise, the demand for effective treatment options is expected to drive the growth of the Opioid Induced Constipation Drug Market in the coming years.
Opioid Induced Constipation Drug Market Route of Administration Insights
The Opioid Induced Constipation Drug Market is segmented by Route of Administration into Oral, Rectal, and Intravenous. Among these, the Oral segment held the largest market share in 2023 and is expected to maintain its dominance throughout the forecast period. The growth of this segment can be attributed to the ease of administration, patient convenience, and cost-effectiveness of oral medications. The Rectal segment is expected to witness a steady growth rate during the forecast period, owing to the increasing adoption of rectal suppositories and enemas for the management of opioid-induced constipation in patients who are unable to tolerate oral medications.
The Intravenous segment is anticipated to account for a smaller market share compared to the Oral and Rectal segments. However, it is expected to exhibit a significant growth rate during the forecast period, primarily due to the increasing use of intravenous medications in hospitalized patients with severe opioid-induced constipation.
Opioid Induced Constipation Drug Market Indication Insights
The Global Opioid-Induced Constipation Drug Market is segmented by Indication into Opioid-Induced Constipation and Non-Opioid-Induced Constipation. The Opioid-Induced Constipation segment accounted for a larger share of the market in 2023 and is projected to continue to dominate the market throughout the forecast period. This is due to the increasing prevalence of opioid-induced constipation, which is a common side effect of opioid use. The Non-Opioid-Induced Constipation segment is also expected to witness significant growth over the forecast period due to the rising incidence of non-opioid-induced constipation, which a variety of factors such as dehydration, certain medications and underlying medical conditions can cause.
Opioid Induced Constipation Drug Market Regional Insights
The Opioid Induced Constipation Drug Market is segmented into North America, Europe, APAC, South America, and MEA. North America held the largest market share in 2023 (0.782 USD Billion) and is expected to maintain its dominance throughout the forecast period (1.185 USD Billion). The high prevalence of opioid-induced constipation in the region, coupled with the availability of advanced healthcare infrastructure and a large patient population, contribute to the significant market size. Europe is another major market for opioid-induced constipation drugs, with a substantial patient population and a well-established healthcare system (0.299 USD Billion in 2023, 0.476 USD Billion in 2032).
The APAC region is expected to witness the fastest growth during the forecast period, owing to the rising incidence of opioid-induced constipation and the increasing adoption of opioid-induced constipation drugs in countries like China and India (0.345 USD Billion in 2023, 0.564 USD Billion in 2032). South America and MEA also represent significant markets for opioid-induced constipation drugs, with a growing patient population and a rising demand for effective treatments (South America: 0.192 USD Billion in 2023, 0.322 USD Billion in 2032; MEA: 0.092 USD Billion in 2023, 0.153 USD Billion in 2032).
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Opioid Induced Constipation Drug Market Key Players And Competitive Insights:
Major players in Opioid Induced Constipation Drug Market industry strive to maintain a competitive edge by investing in research and development (R&D) of novel products and technologies. They engage in mergers and acquisitions to expand their product portfolios and gain access to new markets. Leading Opioid Induced Constipation Drug Market players focus on strengthening their distribution channels to increase their reach and improve customer service. The Opioid Induced Constipation Drug Market is characterized by a high level of competition, with several key players vying for market share. These players implement various strategies to maintain their position and gain an edge over their competitors.
A leading company in the Opioid Induced Constipation Drug Market is Allergan. Allergan is a global pharmaceutical and medical device company that develops, manufactures, and markets a broad portfolio of products. The company offers a range of opioid-induced constipation drugs, such as Linzess (linaclotide) and Movantik (naloxegol). Allergan has a strong presence in key markets around the world and benefits from a wide distribution network. The company invests heavily in R&D, which has resulted in the development of innovative products that meet the evolving needs of patients.
A competitor company in the Opioid Induced Constipation Drug Market is AstraZeneca. AstraZeneca is a multinational pharmaceutical and biopharmaceutical company that specializes in the development and marketing of innovative medicines. The company offers a range of opioid-induced constipation drugs, such as Entereg (alvimopan) and Moventig (naloxegol). AstraZeneca has a strong presence in major markets and a robust pipeline of potential new products. The company focuses on developing therapies that improve patient outcomes and address unmet medical needs.
Key Companies in the Opioid Induced Constipation Drug Market Include
- Salix Pharmaceuticals
- Mallinckrodt
- AstraZeneca
- Intec Pharma
- Impel NeuroPharma
- Cosmo Pharmaceuticals
- Xeris Pharmaceuticals
- Synergy Pharmaceuticals
- Purdue Pharma
- Akcea Therapeutics
- Reliant Pharmaceuticals
- Braintree Laboratories
- BioDelivery Sciences International
- Cara Therapeutics
Opioid-Induced Constipation Drug Industry Developments
The Opioid Induced Constipation Drug Market size was valued at USD 1.71 billion in 2023 and is projected to reach USD 2.70 billion by 2032, exhibiting a CAGR of 5.18% during the forecast period.
Recent developments in the market include the launch of new drugs, such as Naldemedine (Symproic) by Shionogi & Co., Ltd. and Movantik (naloxegol) by AstraZeneca, which have shown promising results in clinical trials. Additionally, the growing prevalence of opioid-induced constipation (OIC) due to the rising use of opioids for pain management is driving the demand for effective treatment options.
Opioid Induced Constipation Drug Market Segmentation Insights
Opioid Induced Constipation Drug Market Opioid Type Outlook
- Agonists
- Partial Agonists
- Mixed Agonists/Antagonists
- Antagonists
Opioid Induced Constipation Drug Market Drug Class Outlook
- Peripherally Acting -Opioid Receptor Antagonists
- Peripherally Acting Non-Opioid Receptor Agonists
- Centrally Acting Laxatives
- Osmotic Laxatives
Opioid Induced Constipation Drug Market Route of Administration Outlook
Opioid Induced Constipation Drug Market Indication Outlook
- Opioid-Induced Constipation
- Non-Opioid-Induced Constipation
Opioid Induced Constipation Drug Market Regional Outlook
- North America
- Europe
- South America
- Asia-Pacific
- Middle East and Africa
Report Attribute/Metric |
Details |
Market Size 2022 |
1.63(USD Billion) |
Market Size 2023 |
1.71(USD Billion) |
Market Size 2032 |
2.7(USD Billion) |
Compound Annual Growth Rate (CAGR) |
5.18% (2024 - 2032) |
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Base Year |
2023 |
Market Forecast Period |
2024 - 2032 |
Historical Data |
2019 - 2022 |
Market Forecast Units |
USD Billion |
Key Companies Profiled |
Salix Pharmaceuticals, Mallinckrodt, AstraZeneca, Intec Pharma, Impel NeuroPharma, Cosmo Pharmaceuticals, Xeris Pharmaceuticals, Synergy Pharmaceuticals, Purdue Pharma, Akcea Therapeutics, Reliant Pharmaceuticals, Braintree Laboratories, BioDelivery Sciences International, Cara Therapeutics |
Segments Covered |
Opioid Type, Drug Class, Route of Administration, Indication, Regional |
Key Market Opportunities |
Rising prevalence of opioid-induced constipation Increasing demand for nonopioid treatment options Growing awareness of the long-term effects of opioid use Technological advancements in drug development Expanding patient population due to aging and chronic conditions |
Key Market Dynamics |
Rising prevalence of opioid use Increasing demand for nonopioid treatments Growth in geriatric population Technological advancements Expansion of healthcare infrastructure |
Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Opioid Induced Constipation Drug Market is expected to reach USD 2.7 billion by 2032, growing at a CAGR of 5.18% from 2024 to 2032.
North America is expected to hold the largest market share in the Opioid Induced Constipation Drug Market, followed by Europe and Asia-Pacific.
The hospital segment is expected to hold the largest market share in the Opioid Induced Constipation Drug Market, followed by the retail pharmacy segment.
Some of the key competitors in the Opioid Induced Constipation Drug Market include Allergan, AstraZeneca, Cosmo Pharmaceuticals, Ironwood Pharmaceuticals, and Pfizer.
The major factors driving the growth of the Global Opioid-Induced Constipation Drug Market include the increasing prevalence of opioid-induced constipation, the growing demand for effective and safe treatments, and the rising awareness of the condition.
The challenges faced by the Opioid Induced Constipation Drug Market include the high cost of treatment, the limited availability of effective drugs, and the potential for side effects.
The opportunities for the Opioid Induced Constipation Drug Market include the development of new and more effective drugs, the expansion of the market into new regions, and the increasing awareness of the condition.
The key trends in the Opioid Induced Constipation Drug Market include the increasing use of combination therapies, the development of new delivery systems, and the growing focus on patient-centered care.
The Opioid Induced Constipation Drug Market is expected to grow from USD 1.71 billion in 2023 to USD 2.7 billion by 2032, at a CAGR of 5.18%.
The key growth strategies for players in the Opioid Induced Constipation Drug Market include expanding their product portfolios, investing in research and development, and forming strategic partnerships.